<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000437</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAMAS11210</org_study_id>
    <secondary_id>R01AA011210</secondary_id>
    <nct_id>NCT00000437</nct_id>
  </id_info>
  <brief_title>Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)</brief_title>
  <official_title>Nalmefene in Nicotine and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched
      placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in
      reducing drinking and smoking in patients with both nicotine and alcohol dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible individuals will be randomly assigned to a 12-week trial of a fixed daily dose of
      either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will
      receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews
      will be conducted 3 and 6 months after treatment to determine smoking and drinking status and
      persistence of any dependence symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 1997</start_date>
  <completion_date type="Actual">September 15, 2005</completion_date>
  <primary_completion_date type="Actual">September 15, 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind tablet and patch active study medications, and matched tablet and patch placebos</masking_description>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alcoholism</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Naltrexone Tablet and Nicotine Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone Tablet and Placebo Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet and Nicotine Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet and Placebo Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Tablet and Nicotine Patch</intervention_name>
    <arm_group_label>Naltrexone Tablet and Nicotine Patch</arm_group_label>
    <other_name>Revia and Nicotrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Tablet and Placebo Patch</intervention_name>
    <arm_group_label>Naltrexone Tablet and Placebo Patch</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet and Nicotine Patch</intervention_name>
    <arm_group_label>Placebo Tablet and Nicotine Patch</arm_group_label>
    <other_name>Nicotrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet and Placebo Patch</intervention_name>
    <arm_group_label>Placebo Tablet and Placebo Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for alcohol dependence and nicotine dependence.

          -  Expresses a desire to cut down or stop drinking and smoking.

        Exclusion Criteria:

          -  Currently meets criteria for dependence on substances other than alcohol and nicotine.

          -  Any history of opiate dependence or evidence of current opiate use.

          -  Significant medical disorders that will increase potential risk or interfere with
             study participation.

          -  Liver function tests more than 3 times normal or elevated bilirubin.

          -  Females who are pregnant, nursing, or not using a reliable method of birth control.

          -  Meets criteria for a major psychiatric disorder and is in need of or currently
             undergoing drug therapy.

          -  Inability to understand and/or comply with the provisions of the protocol and consent
             form.

          -  Treatment with an investigational drug during the previous month.

          -  Chronic treatment with any narcotic-containing medications during the previous month.

          -  Sensitivity to drug as evidenced by adverse drug experiences especially with narcotic-
             containing analgesics or opioid antagonists.

          -  Current treatment with disulfiram (Antabuse) or nicotine replacement therapy.

          -  More than 6 weeks of abstinence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Mason, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>November 2, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 1999</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Barbara J. Mason</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

